GC
IONS icon

Garde Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Garde Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,000
Closed -$230K – 143
2015
Q2 		$230K Hold
4,000
– – 0.07% 133
2015
Q1 		$255K Hold
4,000
– – 0.08% 125
2014
Q4 		$247K Buy
+4,000
New +$197K 0.08% 125

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Garde Capital's IONS Position: Q3 2015 in Review

Garde Capital sold out of Ionis Pharmaceuticals (IONS) in Q3 2015, closing a stake of 4,000 shares — an estimated $230K sold.

Garde Capital first reported a position in IONS in Q4 2014 and held it in 3 quarters. The position peaked at $255K in Q1 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q3 2015.

  • Garde Capital reported no remaining Ionis Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Garde Capital sold 4,000 Ionis Pharmaceuticals shares in Q3 2015, an estimated $230K.
  • Garde Capital first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Garde Capital's Ionis Pharmaceuticals position peaked at $255K in Q1 2015.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2015.

Based on Garde Capital's 13F filing for Q3 2015, filed 17 Nov 2015.